Business Description
Hinova Pharmaceuticals Inc
ISIN : CNE1000059F5
Share Class Description:
SHSE:688302: Class ATotal Employee Number:
241Compare
Compare
Traded in other countries / regions
688302.China Index Membership
SSE Composite Index IPO Date
2022-04-12Description
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.88 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.78 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.66 | |||||
Beneish M-Score | 108.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 125.7 | |||||
3-Year EBITDA Growth Rate | 25.8 | |||||
3-Year EPS without NRI Growth Rate | 20 | |||||
3-Year FCF Growth Rate | 22.9 | |||||
3-Year Book Growth Rate | -12.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.21 | |||||
9-Day RSI | 47.05 | |||||
14-Day RSI | 45.6 | |||||
3-1 Month Momentum % | -10.45 | |||||
6-1 Month Momentum % | -14.37 | |||||
12-1 Month Momentum % | -31.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.04 | |||||
Quick Ratio | 7 | |||||
Cash Ratio | 6.62 | |||||
Days Inventory | 2264.76 | |||||
Days Sales Outstanding | 26.9 | |||||
Days Payable | 110609.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.29 | |||||
Operating Margin % | -324.36 | |||||
Net Margin % | -290.42 | |||||
EBITDA Margin % | -289.95 | |||||
FCF Margin % | -320.92 | |||||
OCF Margin % | -182.28 | |||||
ROE % | -12.28 | |||||
ROA % | -10.14 | |||||
ROIC % | -36.17 | |||||
3-Year ROIIC % | 62.95 | |||||
ROC (Joel Greenblatt) % | -36.53 | |||||
ROCE % | -11.22 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 39.98 | |||||
PS Ratio | 73.04 | |||||
PB Ratio | 3.28 | |||||
Price-to-Tangible-Book | 3.38 | |||||
EV-to-EBIT | -19.24 | |||||
EV-to-EBITDA | -19.24 | |||||
EV-to-Revenue | 55.8 | |||||
EV-to-FCF | -17.39 | |||||
| Price-to-Net-Current-Asset-Value | 5.39 | |||||
| Price-to-Net-Cash | 5.9 | |||||
Earnings Yield (Greenblatt) % | -5.2 | |||||
FCF Yield % | -4.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hinova Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 46.495 | ||
| EPS (TTM) (Â¥) | -1.37 | ||
| Beta | 1.6997 | ||
| 3-Year Sharpe Ratio | -0.12 | ||
| 3-Year Sortino Ratio | -0.2 | ||
| Volatility % | 16.59 | ||
| 14-Day RSI | 45.6 | ||
| 14-Day ATR (Â¥) | 2.10908 | ||
| 20-Day SMA (Â¥) | 35.931 | ||
| 12-1 Month Momentum % | -31.87 | ||
| 52-Week Range (Â¥) | 31.9 - 71.98 | ||
| Shares Outstanding (Mil) | 99.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hinova Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hinova Pharmaceuticals Inc Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hinova Pharmaceuticals Inc Frequently Asked Questions
What is Hinova Pharmaceuticals Inc(SHSE:688302)'s stock price today?
The current price of SHSE:688302 is ¥34.25. The 52 week high of SHSE:688302 is ¥71.98 and 52 week low is ¥31.90.
When is next earnings date of Hinova Pharmaceuticals Inc(SHSE:688302)?
The next earnings date of Hinova Pharmaceuticals Inc(SHSE:688302) is .
Does Hinova Pharmaceuticals Inc(SHSE:688302) pay dividends? If so, how much?
Hinova Pharmaceuticals Inc(SHSE:688302) does not pay dividend.
Press Release
Articles on Hinova Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers